No Data
Three key points to watch in the morning session - Lingering caution towards Trump trade continuation and tariffs.
In the morning of the 11th, the following 3 points are worth noting in the trading. ■ Attention should be paid to Trump trade continuation and lingering caution about tariffs. ■ SoftBank, upward revision on 3/25 Operating profit 950 billion yen ← 900 billion yen. ■ Points of interest in the morning: Consideration of prohibiting continuous work for 14 days or more, possible reassessment of up to 48 days. ■ Attention should be paid to Trump trade continuation and lingering caution about tariffs. The Japanese stock market on the 11th started with a focus on selling, and it seems to develop into a strong market situation. In the U.S. market on the 8th, the Dow Jones Industrial Average
Concerns about tariffs persist despite the continuation of the Trump trade.
On the 11th, the Japanese stock market is likely to develop into a stalemate market situation after starting with selling pressure. On the 8th, the US market saw the Dow Jones Industrial Average rise by 259 points, while the Nasdaq increased by 17 points. Buying due to expectations of policies under the Trump administration continued. In the press conference following the Federal Open Market Committee (FOMC) meeting the previous day, Federal Reserve Chair Powell hinted at further interest rate cuts, and the Michigan Consumer Sentiment Index exceeded financial estimates, leading to a sense of reassurance. Chicago day
SoftBank, 25/3 upward revision operating profit 950 billion yen ← 900 billion yen.
SoftBank <9434> announced a revision to its forecast for the fiscal year ending March 2025. The revenue was revised upward from 6 trillion 200 billion yen to 6 trillion 350 billion yen, and the operating profit from 900 billion yen to 950 billion yen. The strong performance of its subsidiary PayPay, a major player in smart phone payments, as well as the recovery of the mobile business, contributed to this. Positive evaluations for Secom midterm <9735>, Kaken Pharmaceuticals midterm <4521>, Olympus midterm <7733>, Fukui silver revision <8362>, Tokyu midterm <9005>.
Keikyu Corporation Boosts Dividend Amid Strong Performance
Keikyu Corporation Surpasses Profit Forecasts
Keikyu: Confirmatory letter.
No Data
No Data